Fecal transplant is as effective and safe in immunocompromised as non-immunocompromised patients for Clostridium difficile

Int J Colorectal Dis. 2016 May;31(5):1059-1060. doi: 10.1007/s00384-015-2396-2. Epub 2015 Sep 26.

Authors

Amar Mandalia¹, Angela Ward², William Tauxe¹, Colleen S Kraft³, Tanvi Dhere⁴

Affiliations

¹ Emory University School of Medicine, Atlanta, GA, USA.
² Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA, USA.
³ Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
⁴ Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA, USA. tdhere@emory.edu.

No abstract available

Publication types

Letter

MeSH terms

Clostridioides difficile / physiology*
Enterocolitis, Pseudomembranous / therapy*
Fecal Microbiota Transplantation* / adverse effects
Follow-Up Studies
Humans
Immunocompromised Host*

Grants and funding

UL1 TR000454/TR/NCATS NIH HHS/United States